Literature DB >> 25701994

Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis.

Louise C Ivers1, Isabelle J Hilaire2, Jessica E Teng3, Charles P Almazor2, J Gregory Jerome2, Ralph Ternier2, Jacques Boncy4, Josiane Buteau4, Megan B Murray5, Jason B Harris6, Molly F Franke7.   

Abstract

BACKGROUND: Between April and June, 2012, a reactive cholera vaccination campaign was done in Haiti with an oral inactivated bivalent whole-cell vaccine. We aimed to assess the effectiveness of the vaccine in a case-control study and to assess the likelihood of bias in that study in a bias-indicator study.
METHODS: Residents of Bocozel or Grand Saline who were eligible for the vaccination campaign (ie, age ≥12 months, not pregnant, and living in the region at the time of the vaccine campaign) were included. In the primary case-control study, cases had acute watery diarrhoea, sought treatment at one of three participating cholera treatment units, and had a stool sample positive for cholera by culture. For each case, four control individuals who did not seek treatment for acute watery diarrhoea were matched by location of residence, enrolment time (within 2 weeks of the case), and age (1-4 years, 5-15 years, and >15 years). Cases in the bias-indicator study were individuals with acute watery diarrhoea with a negative stool sample for cholera. Controls were selected in the same manner as in the primary case-control study. Trained staff used standard laboratory procedures to do rapid tests and stool cultures from study cases. Participants were interviewed to collect data on sociodemographic characteristics, risk factors for cholera, and self-reported vaccination. Data were analysed by conditional logistic regression, adjusting for matching factors.
FINDINGS: From Oct 24, 2012, to March 9, 2014, 114 eligible individuals presented with acute watery diarrhoea and were enrolled, 25 of whom were subsequently excluded. 47 participants were analysed as cases in the vaccine effectiveness case-control study and 42 as cases in the bias-indicator study. 33 (70%) of 47 cholera cases self-reported vaccination versus 167 (89%) of 188 controls (vaccine effectiveness 63%, 95% CI 8-85). 27 (57%) of 47 cases had certified vaccination versus 147 (78%) of 188 controls (vaccine effectiveness 58%, 13-80). Neither self-reported nor verified vaccination was significantly associated with non-cholera diarrhoea (vaccine effectiveness 18%, 95% CI -208 to 78 by self-report and -21%, -238 to 57 by verified vaccination).
INTERPRETATION: Bivalent whole-cell oral cholera vaccine effectively protected against cholera in Haiti from 4 months to 24 months after vaccination. Vaccination is an important component of efforts to control cholera epidemics. FUNDING: National Institutes of Health, Delivering Oral Vaccines Effectively project, and Department of Global Health and Social Medicine at Harvard Medical School.
Copyright © 2015 Ivers et al. Open Access article distributed under the terms of CC BY-NC-ND. Published by .. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25701994      PMCID: PMC4384694          DOI: 10.1016/S2214-109X(14)70368-7

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN: 2214-109X            Impact factor:   26.763


  26 in total

1.  Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data.

Authors:  H K Ury
Journal:  Biometrics       Date:  1975-09       Impact factor: 2.571

2.  Relationship between neighbourhood-level killed oral cholera vaccine coverage and protective efficacy: evidence for herd immunity.

Authors:  Michael Emch; Mohammad Ali; Jin-Kyung Park; Mohammad Yunus; David A Sack; John D Clemens
Journal:  Int J Epidemiol       Date:  2006-05-24       Impact factor: 7.196

3.  Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru.

Authors:  D N Taylor; V Cárdenas; J L Sanchez; R E Bégué; R Gilman; C Bautista; J Perez; R Puga; A Gaillour; R Meza; P Echeverria; J Sadoff
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

4.  Case-control studies of the effectiveness of vaccines: validity and assessment of potential bias.

Authors:  Eugene D Shapiro
Journal:  Pediatr Infect Dis J       Date:  2004-02       Impact factor: 2.129

5.  Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.

Authors:  Dipika Sur; Anna Lena Lopez; Suman Kanungo; Allison Paisley; Byomkesh Manna; Mohammad Ali; Swapan K Niyogi; Jin Kyung Park; Banawarilal Sarkar; Mahesh K Puri; Deok Ryun Kim; Jacqueline L Deen; Jan Holmgren; Rodney Carbis; Raman Rao; Thu Van Nguyen; Allan Donner; Nirmal K Ganguly; G Balakrish Nair; Sujit K Bhattacharya; John D Clemens
Journal:  Lancet       Date:  2009-10-08       Impact factor: 79.321

6.  5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.

Authors:  Sujit K Bhattacharya; Dipika Sur; Mohammad Ali; Suman Kanungo; Young Ae You; Byomkesh Manna; Binod Sah; Swapan K Niyogi; Jin Kyung Park; Banwarilal Sarkar; Mahesh K Puri; Deok Ryun Kim; Jacqueline L Deen; Jan Holmgren; Rodney Carbis; Mandeep Singh Dhingra; Allan Donner; G Balakrish Nair; Anna Lena Lopez; Thomas F Wierzba; John D Clemens
Journal:  Lancet Infect Dis       Date:  2013-10-18       Impact factor: 25.071

7.  Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.

Authors:  Richelle C Charles; Isabelle J Hilaire; Leslie M Mayo-Smith; Jessica E Teng; J Gregory Jerome; Molly F Franke; Amit Saha; Yanan Yu; Paul Kováč; Stephen B Calderwood; Edward T Ryan; Regina C LaRocque; Charles P Almazor; Firdausi Qadri; Louise C Ivers; Jason B Harris
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

8.  Use of Vibrio cholerae vaccine in an outbreak in Guinea.

Authors:  Francisco J Luquero; Lise Grout; Iza Ciglenecki; Keita Sakoba; Bala Traore; Melat Heile; Alpha Amadou Diallo; Christian Itama; Anne-Laure Page; Marie-Laure Quilici; Martin A Mengel; Jose Maria Eiros; Micaela Serafini; Dominique Legros; Rebecca F Grais
Journal:  N Engl J Med       Date:  2014-05-29       Impact factor: 91.245

9.  Methods to assess the impact of mass oral cholera vaccination campaigns under real field conditions.

Authors:  Jacqueline Deen; Mohammad Ali; David Sack
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

10.  Cholera vaccination campaign contributes to improved knowledge regarding cholera and improved practice relevant to waterborne disease in rural Haiti.

Authors:  Omowunmi Aibana; Molly F Franke; Molly Franke; Jessica E Teng; Jessica Teng; Johanne Hilaire; Max Raymond; Louise C Ivers
Journal:  PLoS Negl Trop Dis       Date:  2013-11-21
View more
  35 in total

1.  Evaluation of Knowledge and Practices Regarding Cholera, Water Treatment, Hygiene, and Sanitation Before and After an Oral Cholera Vaccination Campaign-Haiti, 2013-2014.

Authors:  Lana Childs; Jeannot François; Alina Choudhury; Kathleen Wannemuehler; Amber Dismer; Terri B Hyde; Catherine Y Yen; Kashmira A Date; Stanley Juin; Mark A Katz; Erica Felker Kantor; Janell Routh; Melissa Etheart; Tracie Wright; Paul Adrien; Rania A Tohme
Journal:  Am J Trop Med Hyg       Date:  2016-10-31       Impact factor: 2.345

2.  Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up.

Authors:  Karine Sévère; Vanessa Rouzier; Stravinsky Benedict Anglade; Claudin Bertil; Patrice Joseph; Alexandra Deroncelay; Marie Marcelle Mabou; Peter F Wright; Florence Duperval Guillaume; Jean William Pape
Journal:  Am J Trop Med Hyg       Date:  2016-02-29       Impact factor: 2.345

3.  Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies.

Authors:  Marc Lipsitch; Ayan Jha; Lone Simonsen
Journal:  Int J Epidemiol       Date:  2016-12-01       Impact factor: 7.196

4.  Comparison of two control groups for estimation of oral cholera vaccine effectiveness using a case-control study design.

Authors:  Molly F Franke; J Gregory Jerome; Wilfredo R Matias; Ralph Ternier; Isabelle J Hilaire; Jason B Harris; Louise C Ivers
Journal:  Vaccine       Date:  2017-09-12       Impact factor: 3.641

Review 5.  Diagnosis, Management, and Future Control of Cholera.

Authors:  Fahima Chowdhury; Allen G Ross; Md Taufiqul Islam; Nigel A J McMillan; Firdausi Qadri
Journal:  Clin Microbiol Rev       Date:  2022-06-21       Impact factor: 50.129

6.  Eliminating Cholera Transmission in Haiti.

Authors:  Louise C Ivers
Journal:  N Engl J Med       Date:  2016-12-07       Impact factor: 91.245

Review 7.  Cholera: an overview with reference to the Yemen epidemic.

Authors:  Ali A Rabaan
Journal:  Front Med       Date:  2018-06-22       Impact factor: 4.592

Review 8.  Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era.

Authors:  Sachin N Desai; Lorenzo Pezzoli; Kathryn P Alberti; Stephen Martin; Alejandro Costa; William Perea; Dominique Legros
Journal:  Hum Vaccin Immunother       Date:  2017-03-04       Impact factor: 3.452

9.  Cholera.

Authors:  William Davis; Rupa Narra; Eric D Mintz
Journal:  Curr Epidemiol Rep       Date:  2018-07-27

10.  Decades of cholera in Odisha, India (1993-2015): lessons learned and the ways forward.

Authors:  Hemant Kumar Khuntia; Thandavarayan Ramamurthy; Madhusmita Bal; Sanghamitra Pati; Manoranjan Ranjit
Journal:  Epidemiol Infect       Date:  2021-06-07       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.